Why a Topical Cannabidiol Gel May Help Treat the Behavioral Symptoms of Fragile X

Co-director of the molecular diagnostics section of the Genetic Laboratory at Rush Medical College Elizabeth Berry-Kravis and Zynerba Chairman and CEO Armando Anido, discuss Fragile X, the company’s experimental therapy Zygel, and why the topical cannibidol gel may hold promise for treating the behavioral symptoms of the condition.